blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1805139

EP1805139 - THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  23.09.2016
Database last updated on 21.01.2025
Most recent event   Tooltip23.09.2016Application deemed to be withdrawnpublished on 26.10.2016  [2016/43]
Applicant(s)For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612 / US
[N/P]
Former [2008/36]For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine CA 92612 / US
Former [2007/28]For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612 / US
Inventor(s)01 / IM, Wha, Bin
70 Palatine 305
Irvine, CA 92612 / US
02 / DONDE, Yariv
24386 Antilles Way
Dana Point, CA 92629 / US
03 / HOLOBOSKI, Mark
29342 Bobolink Drive
Laguna Niguel, CA 92677 / US
04 / OLD, David, W.
13771 Typee Way
Irvine, CA 92620 / US
05 / KEDZIE, Karen, M.
11 La Sinfonia
Rancho Santa Margarita, CA 92688 / US
06 / GIL, Daniel, W.
2541 Point del Mar
Corona del Mar, CA 92625 / US
07 / DONELLO, John, E.
34041 Pequito Drive
Dana Point, CA 92629 / US
08 / BURK, Robert, M.
1337 Cerritos Drive
Laguna Beach, CA 92651 / US
09 / GAC, Todd, S.
53 Meadow Valley
Irvine, CA 92602 / US
 [2007/28]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
[N/P]
Former [2007/28]HOFFMANN EITLE
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München / DE
Application number, filing date05817142.224.10.2005
[2007/28]
WO2005US38303
Priority number, dateUS20040622422P26.10.2004         Original published format: US 622422 P
[2007/28]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006047476
Date:04.05.2006
Language:EN
[2006/18]
Type: A2 Application without search report 
No.:EP1805139
Date:11.07.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 04.05.2006 takes the place of the publication of the European patent application.
[2007/28]
Search report(s)International search report - published on:EP28.09.2006
ClassificationIPC:C07C405/00, A61K31/557, A61K31/559, A61K47/48, A61P29/00
[2008/16]
CPC:
C07C405/00 (EP,US); A61K47/549 (EP,US); A61K47/64 (EP,US);
A61P1/00 (EP); A61P29/00 (EP); A61P37/02 (EP);
A61P43/00 (EP) (-)
Former IPC [2007/28]C07C405/00, A61K31/557, A61K47/48
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/28]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:THERAPEUTISCHE UND VERABREICHUNGSVERFAHREN VON PROSTAGLANDIN-EP4-AGONISTEN[2007/28]
English:THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS[2007/28]
French:METHODES THERAPEUTIQUES ET D'ADMINISTRATION D'AGONISTES DE PROSTAGLANDINE EP4[2007/28]
Entry into regional phase16.04.2007National basic fee paid 
16.04.2007Designation fee(s) paid 
16.04.2007Examination fee paid 
Examination proceduredeletedCommunication of intention to grant the patent
16.04.2007Amendment by applicant (claims and/or description)
16.04.2007Examination requested  [2007/28]
03.04.2008Despatch of a communication from the examining division (Time limit: M04)
08.08.2008Reply to a communication from the examining division
03.05.2016Application deemed to be withdrawn, date of legal effect  [2016/43]
16.06.2016Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2016/43]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.04.2008
Fees paidRenewal fee
29.10.2007Renewal fee patent year 03
27.10.2008Renewal fee patent year 04
26.10.2009Renewal fee patent year 05
25.10.2010Renewal fee patent year 06
25.10.2011Renewal fee patent year 07
25.10.2012Renewal fee patent year 08
28.10.2013Renewal fee patent year 09
27.10.2014Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
31.10.201511   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[IX]JPS5052047  ;
 [X]EP0287036  (ONO PHARMACEUTICAL CO [JP]) [X] 1,16 * compound G *;
 [Y]EP0985663  (ONO PHARMACEUTICAL CO [JP]) [Y] 1-6 * abstract * * examples *;
 [Y]EP1097922  (ONO PHARMACEUTICAL CO [JP]) [Y] 1-5 * paragraphs [0047] , [0049] * * tables 1,2,4 * * paragraph [0045] * * compounds of examples 1(1)-1(8), 3(1), 3(2), 3(4), 3(5), 3(7), 6 *;
 [X]US2002002140  (HOLICK MICHAEL F [US], et al) [X] 1-3 * paragraphs [0107] - [0134] *;
 [D]WO03009872  (ONO PHARMACEUTICAL CO [JP], et al);
 [D]US6538018  (BURK ROBERT M [US], et al);
 [DY]US6586468  (MARUYAMA TORU [JP], et al) [DY] 1-4 * tables 1,3,7,9,13,15 * * column 36, lines 45-67 * * column 47, line 40 - column 48, line 3 *;
 [Y]EP1417975  (ONO PHARMACEUTICAL CO [JP]) [Y] 1-6 * paragraphs [0185] , [0705] * * tables 1,11,21,31,41,51-56,59-62, 111,113,115 * * tables 6-10,16-20,26-30,36-40,46-50,67-94, 110,112,114,116 *;
 [Y]US2004102499  (WOODWARD DAVID F [US], et al) [Y] 1-6 * paragraphs [0017] - [0028] * * paragraph [0046] * * examples *;
 [PX]US2005222094  (BURK ROBERT M [US], et al) [PX] 1-6 * paragraphs [0039] , [0062] - [0065] - [0135] * * examples *;
 [X]  - ANDERSON, BRADLEY D. ET AL, "Prostaglandin prodrugs . VI: Structure-thermodynamic activity and structure-aqueous solubility relationships", JOURNAL OF PHARMACEUTICAL SCIENCES , 69(4), 424-30 CODEN: JPMSAE; ISSN: 0022-3549, (1980), XP008060923 [X] 1,16 * page 424, column 1, paragraph 2 * * Table I, N-acetyl-L-tyrosinamide and N-Benzoyl-L-tyrosinamide derivatives *

DOI:   http://dx.doi.org/10.1002/jps.2600690417
 [X]  - AKAMATSU K ET AL, "SYNTHESIS AND BIODISTRIBUTION STUDY OF LIVER-SPECIFIC PROSTAGLANDINE1 POLYMERIC CONJUGATE", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, (1997), vol. 155, no. 1, ISSN 0378-5173, pages 65 - 74, XP002926547 [X] 1,16 * abstract *

DOI:   http://dx.doi.org/10.1016/S0378-5173(97)00159-2
 [IX]  - DATABASE WPI, 0, Derwent World Patents Index, Database accession no. 1975-61200W, XP002370551 & JPS5052047 A 19750509 (ONO PHARM CO LTD) [IX] 1,16 * abstract *
 [DY]  - KABASHIMA K ET AL, "The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut", JOURNAL OF CLINICAL INVESTIGATION 2002 UNITED STATES, (2002), vol. 109, no. 7, ISSN 0021-9738, pages 883 - 893, XP002370491 [DY] 1-5 * figures 3,5,6 * * page 892, column 2, paragraph 3 *

DOI:   http://dx.doi.org/10.1172/JCI200214459
 [Y]  - MARUYAMA T ET AL, "DESIGN AND SYNTHESIS OF A SELECTIVE EP4-RECEPTOR AGONIST. PART 4: PRACTICAL SYNTHESIS AND BIOLOGICAL EVALUTION OF A NOVEL HIGHLY SELECTIVE EP4-RECEPTOR AGONIST", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, (2002), vol. 10, ISSN 0968-0896, pages 2103 - 2110, XP001222023 [Y] 1-5 * compounds 1a,1b *

DOI:   http://dx.doi.org/10.1016/S0968-0896(02)00085-8
 [Y]  - KAJINO HIROKI ET AL, "An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo", PEDIATRIC RESEARCH, (200410), vol. 56, no. 4, ISSN 0031-3998, pages 586 - 590, XP002370490 [Y] 1-5 * abstract *

DOI:   http://dx.doi.org/10.1203/01.PDR.0000139409.25014.35
 [Y]  - YOSHIDA K ET AL, "Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 02 APR 2002 UNITED STATES, (20020402), vol. 99, no. 7, ISSN 0027-8424, pages 4580 - 4585, XP002370559 [Y] 1-6 * figure 4a *

DOI:   http://dx.doi.org/10.1073/pnas.062053399
 [Y]  - FRIEND D R ET AL, "COLON-SPECIFIC DRUG DELIVERY FROM A GLUCOSIDE PRODRUG IN THE GUINEA-PIG. EFFICACY STUDY", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (199102), vol. 15, no. 1, ISSN 0168-3659, pages 47 - 54, XP000200509 [Y] 1-6 * abstract *

DOI:   http://dx.doi.org/10.1016/0168-3659(91)90102-J
 [Y]  - CHOURASIA M K ET AL, "Polysaccharides for Colon Targeted Drug Delivery", DRUG DELIVERY: JOURNAL OF DELIVERY AND TARGETING OF THERAPEUTIC AGENTS 2004 UNITED STATES, (2004), vol. 11, no. 2, ISSN 1071-7544, pages 129 - 148, XP008060983 [Y] 1-6 * the whole document *

DOI:   http://dx.doi.org/10.1080/10717540490280778
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.